Bifidobacterium breve CCFM1025 and Bifidobacterium breve JSWX22M4 treatment significantly improved synaptic plasticity and increased BDNF and fibronectin type III domain-containing protein 5, and postsynaptic density protein 95, thus delaying the pathological development of AD. Here, FNDC5 is linked to Alzheimer disease.